Aletha Maybank to step down as AMA’s chief health equity officer
Aletha Maybank, who became the American Medical Association’s first chief equity officer five and half years ago, is leaving the organization.
Related Articles
Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease, 2020 to 2050
This decision analytical modeling study estimates the burden of metabolic dysfunction–associated steatotic liver disease among US adults from 2020 to 2050.
Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
Scientific Reports – Neurological post-COVID syndrome is associated with substantial impairment of verbal short-term and working memory
‘No Cause for Panic’ as Sperm Counts Found To Be Steady
Several high-profile papers had suggested that sperm counts have drastically fallen globally over the past few decades. In contrast, new data from Cleveland Clinic suggest…
Ethics and corridor care: a contradiction in terms?
In the midst of huge winter pressures, NHS principles on care in “temporary escalation spaces” threaten to take leave from reality In September 2024 NHS…
Odds of Opioid Misuse Lower in States With Medical Cannabis Laws
THURSDAY, Jan. 16, 2025 (HealthDay News) — For individuals reporting cannabis use, the odds of opioid misuse are reduced among individuals in states with medic
Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial
Semaglutide 7.2 mg achieved statistically significant and superior weight loss at 72 weeks versus placebo, hitting the Phase 3b trial’s primary endpoint.
It May Be Easier to Quit Smoking With Holistic or Integrated Health Approach
TUESDAY, Jan. 14, 2025 (HealthDay News) — It takes a village to help a smoker quit.And a new study published recently in JAMA Internal Medicine…
AstraZeneca, Daiichi Sankyo win first U.S. approval for key cancer drug
A drug from AstraZeneca and Daiichi Sankyo won authorization for a form of breast cancer, the first U.S. approval for the closely watched treatment.
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
Eli Lilly’s CEO says the company is considering offering more Zepbound doses in vials at lower cost.
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes…
